<?xml version="1.0" encoding="UTF-8"?>
<p>The broad-spectrum antiviral agent, umifenovir, or arbidol hydrochloride, was developed 25 years ago at the Russian Research Chemical and Pharmaceutical Institute. Umifenovir is approved for the prophylaxis and treatment of human influenza type A and type B infections, as well as post-influenza complications (only in a few countries including Russia and China), [
 <xref rid="B37-pharmaceuticals-13-00096" ref-type="bibr">37</xref>]. Overall, umifenovir has a broad variety of antiviral activity against hepatitis B virus, respiratory syncytial virus, adenovirus, parainfluenza virus, avian coronavirus, coxsackie B3 virus, hantavirus, and arthropod-borne flaviviruses including Zika virus, West Nile virus, and tick-borne encephalitis, thus indicating broad-spectrum antiviral activities [
 <xref rid="B38-pharmaceuticals-13-00096" ref-type="bibr">38</xref>]. A current trial on mild cases of COVID-19 is investigating the drug as either a single treatment or in combination with pegylated interferon-Î² atomization for two weeks (NCT04254874).
</p>
